Edgestream Partners L.P. Makes New $3.48 Million Investment in Repligen Corporation $RGEN

Edgestream Partners L.P. purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 28,008 shares of the biotechnology company’s stock, valued at approximately $3,484,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Twin Tree Management LP bought a new stake in Repligen in the 1st quarter valued at $29,000. Hantz Financial Services Inc. lifted its holdings in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares in the last quarter. Center for Financial Planning Inc. lifted its holdings in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Repligen during the second quarter worth about $104,000. Finally, Hilltop National Bank bought a new position in shares of Repligen during the second quarter worth about $147,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

NASDAQ RGEN opened at $166.52 on Thursday. The firm has a market capitalization of $9.37 billion, a P/E ratio of 8,330.17, a price-to-earnings-growth ratio of 3.74 and a beta of 1.11. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average price is $152.19 and its two-hundred day moving average price is $132.61. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The company’s quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Insider Buying and Selling

In other Repligen news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony Hunt sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total value of $3,922,000.00. Following the completion of the sale, the director directly owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 49,382 shares of company stock worth $7,676,802. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on RGEN shares. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Barclays boosted their price objective on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Wednesday, September 3rd. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. Finally, Evercore ISI boosted their price target on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.